Cherwell Provides Practical Microbiolo?gical Solutions at PHSS 2013
Cherwell Laboratories will be offering expert knowledge and demonstrating their comprehensive range of specialist environmental monitoring and process validation products at the forthcoming PHSS Annual Members Conference 2013, Microbial Aspects of Cleanroom Manufacture.
The annual conference, to be held at Wychwood Park Hotel, Crewe on 9 & 10 October 2013, coincides with the release of the new PHSS Bio-contamination technical monograph 20. Presentations throughout the event, which is free-to-attend for PHSS members, will feature key aspects of Bio-contamination management as detailed in this new publication.
Andrew Barrow, Sales Manager, Cherwell Laboratories commented: “This event will provide an invaluable insight into Bio-contamination management and the new PHSS technical monograph 20.” He added, “Cherwell will be available throughout the event to share practical ideas with delegates on their specific environmental monitoring or process validation requirements.”
With more than 40 years’ experience in the pharmaceutical and healthcare sciences industry, Cherwell Laboratories has developed a specialist range of products to meet the specific requirements of environmental monitoring and process validation. The Cherwell range includes Redipor prepared media; a selection of petri dishes, settle plates, bottled media, broth bags, vials and ampoules. Other products in the range include SAS microbial air samplers for a variety of environmental monitoring applications and biological indicators for the validation of sterilisation processes.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...